Astellas, FibroGen get extended Roxadustat approval in Japan for anemia of CKD
Roxadustat approval - Astellas Pharma and FibroGen have secured approval for EVRENZO (roxadustat) in Japan for the treatment of anemia associated with chronic kidney disease ... Read More
Walmart to sell 85% stake in Japanese supermarket chain Seiyu to KKR and Rakuten
Walmart has agreed to sell a stake of 85% in Seiyu, a Japanese supermarket chain, to KKR and a subsidiary of Rakuten, for a combined ... Read More
Sano Solar Power Plant : Pacifico Energy breaks ground on 54MW plant in Japan
Pacifico Energy has broken ground on the 53.9MW (DC) Sano Solar Power Plant in Sano-shi, Tochigi Prefecture in Japan. The Sano Solar project marks the ... Read More
Danone sells remaining stake in probiotic milk beverage maker Yakult Honsha
French food company Danone has sold its remaining stake of 6.61% in Yakult Honsha, the maker of Japanese sweetened probiotic milk beverage Yakult, for JPY ... Read More
NEC to acquire Swiss fintech company Avaloq for $2.2bn
NEC acquisition of Avaloq : NEC Corporation, a Japanese IT and electronics company, has agreed to acquire Avaloq Group, a Swiss financial software company, for ... Read More
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission ... Read More
Japan-based Santen acquires US ophthalmic company Eyevance Pharmaceuticals
Santen acquisition of Eyevance : Santen Pharmaceutical, a Japanese pharma company specialized in ophthalmology, has acquired US ophthalmic company Eyevance Pharmaceuticals for $225 million in ... Read More
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. ... Read More
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More
Takeda to sell select non-core assets to Cheplapharm for $562m
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm ... Read More